20 slides from Genfleet Therapeutics (shanghai), Inc. Class H's conference presentation, September 2026
Slide 1: 2026 WCLC: GFH375 Oral Presentation Data Review
2026 WCLC: GFH375 Oral Presentation Data Review Sept. 2026 1
Slide 2: Contents
Contents 1 Study background of GFH375 across tumor types 2 GFH375 oral presentation study data review 3 Q&A 4 Summary and outlook 2
Slide 3: Copyright, disclaimer and forward-looking statements
Copyright, disclaimer and forward-looking statements Specific information in this presentation may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "predict", "expect", "will"
Slide 4: Study background of GFH375 across tumor types
O07 Study background of GFH375 across tumor types
Slide 5: From FPI to Global Stage: Druggability, Execution and Results
From FPI to Global Stage: Druggability, Execution and Results 2024 2025 2026 2024.7 FPI 2025.6 ASCO Oral First patient dosed in 66 pts’ data in solid-tumor trial China’s study D+11Months 2025.9 WCLC Oral 2026.2 NSCLC BTD Start Point of First in China to have received BTD for 142 pts data in solid-tu
Slide 6: Robust Druggability Supported by Consistent Efficacy and Safety Profile
Robust Druggablity Supported by Consistent Efficacy and Safety Profile GFH375’s promising efficacy across multiple malignancies earns commentator recognition at 2026 ASCO We see a truly impressive response rate in CCA, a refractory disease. And I will mention that we saw data earlier for this agent
Slide 7: GFH375 oral presentation study data review
WA, GFH375 oral presentation study data review
Slide 8: Objective Response
Objective Response • Among the 71 patients with at least one post-treatment efficacy • Median (range) time to response: 1.4 months (1.4-8.3 months) evaluation, ORR was 59.2% (42/71), confirmed ORR was 52.1% (37/71). • Median duration of response: 8.3 months (95% CI: 6.3, NA) • Among the 9 patients w
Slide 9: PFS and OS
PFS and OS • Median PFS was 8.3 months (95% CI: 6.8, NA) with median follow-up time 11.0 months. ◦ Among taxane-naïve patients, median PFS was 9.6 months (95% CI: 6.7, NA) ◦ Among taxane-pretreated patients, median PFS was 8.1 months (95% CI: 5.5, NA) • Median OS was not reached (95% CI: 15.4 m, NA)
Slide 10: Safety in Patients with NSCLC
Safety in Patients with NSCLC • GFH375 presented a manageable safety profile in pretreated NSCLC patients. • The safety profile was consistent with prior reports1-3, without new safety signals. • Common TRAEs were gastrointestinal, hematological AEs and transaminitis; most were grade 1 or 2 and reco
Slide 11: Three KRAS G12D Inhibitors Advance into Phase III Treating NSCLC
Three KRAS G12D Inhibitors Advance into Phase III Treating NSCLC Ph I/II mono trial in 2L+ NSCLC Initiation of PhIII trial for Compay Product Sample size for Confirmed NSCLC RP2D DCR Cutoff date efficacy data ORR Sept. 4, 2026 2026.7 GenFleet GFH375 600 mg QD 71 52.1% 93% （2026 WCLC） （mono) - 2026.8
Slide 12: Cross-trial Comparison – Baseline Characteristics in 2L+ NSCLC
Cross-trial Comparison – Baseline Characteristics in 2L+ NSCLC GFH375 600 mg QD (N=75) RMC-9805 1200 mg QD (N=27) Trial NCT06500676 NCT06040541 Prior lines of 1-4 1-2 therapy （42.7% ≥2 prior lines, 22.7% ≥3 prior lines） （67% with one prior line, 33% with two prior lines） • ICI • ICI • Platinum-based
Slide 13: Cross-trial Comparison – Efficacy in 2L+ NSCLC
Cross-trial Comparison – Efficacy in 2L+ NSCLC GFH375 600 mg QD RMC-9805 1200 mg QD Confirmed ORR 52.1% (95%CI: 39.9%, 64.1%) 52% (95%CI: 32%, 71%) DCR 93% (95% CI: 84.3%, 97.7%) 93% (95%CI: 76%, 99%) Median follow-up 11m 13.1m • 9.6m (95% CI: 6.7, NA) – taxane (including docetaxel)-naïve patients 1
Slide 14: Cross-trial Comparison – Safety in 2L+ NSCLC and Solid Tumor Patients
Cross-trial Comparison – Safety in 2L+ NSCLC and Solid Tumor Patients VS-7375 600-900 mg QD GFH375 600 mg QD American solid tumor pts，after 1 cycle (≥29 days) RMC-9805 1200 mg QD in （N=75，Chinese NSCLC American NSCLC patients patients） 600 mg QD （N=51) 900 mg QD (N=22） (N=40) Diarrhea 78.7% 24% 18%
Slide 15: Q&A
O03 Q&A
Slide 16: Summary and outlook
04 Summary and outlook
Slide 17: Two RAS Inhibitors’ Study Data Accepted for Full Submission of LBA at 2026 ESMO
Two RAS Inhibitors’ Study Data Accepted for Full Submission of LBA at 2026 ESMO GFH375 combined with cetux GFH276 KRAS + EGFR Pan RAS inhibitor Combo/PDAC, CRC Mono/Solid tumors 17
Slide 18: Recap of GFH375 Phase I Data Published in Nature Medicine
Recap of GFH375 Phase I Data Published in Nature Medicine 52.5 Impact Factor Phase I treating KRAS G12D-mutant solid tumors Published online on Sept. 15 18
Slide 19: Six Launches in 2026/2027 Support Solid Commercialization Prospects
Six Launches in 2026/2027 Support Solid Commercialization Prospects GFH375（KRAS G12D inhibitor） GFH276（Pan RAS inhibitor） PDAC PDAC Late-line, mono 1st-line, combo with chemo Late-line, mono NSCLC CRC 1st-line, combo with chemo Late-line, mono 3rd-line, combo with cetux 19
Slide 20: Innovation, in expedition
3 Led Innovation, in expedition a